Reliability and Validity of the MD Anderson Symptom Inventory (MDASI-BT) in the Primary Brain Tumor Patient Population

2.50
Hdl Handle:
http://hdl.handle.net/10755/165317
Category:
Abstract
Type:
Presentation
Title:
Reliability and Validity of the MD Anderson Symptom Inventory (MDASI-BT) in the Primary Brain Tumor Patient Population
Author Details:
T. Armstrong, MD Anderson Cancer Center, Houston, Texas, USA; T. Mendoza; M. Cohen; M. Morrissey; C. Cleeland; M. Gilbert
Abstract:
The occurrence of multiple symptoms has been shown to impact patient outcomes, such as quality of life, mood, disease progression, and survival in other solid tumor patients. The occurrence of multiple symptoms in patients with primary brain tumors has not been routinely measured. Tools specifically designed to measure multiple symptoms in persons with cancer have been developed for use in patients with other solid tumors. No instrument has been validated which includes both neurologic symptoms and symptoms commonly associated with cancer and its treatment. Purpose: The aim of this study is to validate the M.D. Anderson Symptom Inventory–Brain Tumor Module (MDASI-BT) in patients who have primary brain tumors and to evaluate the occurrence and severity of selected symptoms in this patient population. Theoretical/Scientific Framework: This study is guided by the Symptoms Experience conceptual framework. This framework views symptoms as the frequency, intensity, distress, and meaning of symptoms as they are produced, perceived and expressed. Symptoms are multiplicative and nature and may act as catalysts for the occurrence of other symptoms. Antecedents to the symptoms experience includes demographic, disease, and individual factors. Consequences include the impact on mood state, psychological status, functional status, quality of life, disease progression and survival. Methods: The study will evaluate the reliability and validity of the MDASI-BT in 200 adult primary brain tumor patients. Demographic and disease related data will be collected at the time the MDASI-BT is completed. Data Analysis: Reliability will be assessed by calculation of Cronbach’s alpha. Construct validity will be determined using confirmatory factor analysis. In addition, descriptive statistics will be used to describe how patients rate symptom severity and interference with function. Finally, we will examine the relationship of symptom severity to diagnosis, concomitant medications, Karnnofsky performance status, and where the patient is in treatment. Findings and Implications: Validation of a tool to measure the occurrence of multiple symptoms in the brain tumor population is the first step in a program of research concerning the evaluation of symptom clusters and the effectiveness of interventions in reducing or eliminating these symptoms.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2005
Conference Name:
30th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Orlando, Florida, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleReliability and Validity of the MD Anderson Symptom Inventory (MDASI-BT) in the Primary Brain Tumor Patient Populationen_GB
dc.author.detailsT. Armstrong, MD Anderson Cancer Center, Houston, Texas, USA; T. Mendoza; M. Cohen; M. Morrissey; C. Cleeland; M. Gilberten_US
dc.identifier.urihttp://hdl.handle.net/10755/165317-
dc.description.abstractThe occurrence of multiple symptoms has been shown to impact patient outcomes, such as quality of life, mood, disease progression, and survival in other solid tumor patients. The occurrence of multiple symptoms in patients with primary brain tumors has not been routinely measured. Tools specifically designed to measure multiple symptoms in persons with cancer have been developed for use in patients with other solid tumors. No instrument has been validated which includes both neurologic symptoms and symptoms commonly associated with cancer and its treatment. Purpose: The aim of this study is to validate the M.D. Anderson Symptom Inventory–Brain Tumor Module (MDASI-BT) in patients who have primary brain tumors and to evaluate the occurrence and severity of selected symptoms in this patient population. Theoretical/Scientific Framework: This study is guided by the Symptoms Experience conceptual framework. This framework views symptoms as the frequency, intensity, distress, and meaning of symptoms as they are produced, perceived and expressed. Symptoms are multiplicative and nature and may act as catalysts for the occurrence of other symptoms. Antecedents to the symptoms experience includes demographic, disease, and individual factors. Consequences include the impact on mood state, psychological status, functional status, quality of life, disease progression and survival. Methods: The study will evaluate the reliability and validity of the MDASI-BT in 200 adult primary brain tumor patients. Demographic and disease related data will be collected at the time the MDASI-BT is completed. Data Analysis: Reliability will be assessed by calculation of Cronbach’s alpha. Construct validity will be determined using confirmatory factor analysis. In addition, descriptive statistics will be used to describe how patients rate symptom severity and interference with function. Finally, we will examine the relationship of symptom severity to diagnosis, concomitant medications, Karnnofsky performance status, and where the patient is in treatment. Findings and Implications: Validation of a tool to measure the occurrence of multiple symptoms in the brain tumor population is the first step in a program of research concerning the evaluation of symptom clusters and the effectiveness of interventions in reducing or eliminating these symptoms.en_GB
dc.date.available2011-10-27T12:16:22Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:16:22Z-
dc.conference.date2005en_US
dc.conference.name30th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationOrlando, Florida, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.